Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 7, 2013, Pages 2212-2216

  Sifferlen, Thierry ^a   Koberstein, Ralf ^a   Cottreel, Emmanuelle ^a   Boller, Amandine ^a   Weller, Thomas ^a   Gatfield, John ^a   Brisbare Roch, Catherine ^a   Jenck, Francois ^a   Boss, Christoph ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

5,6,7,8 Tetrahydroimidazo 1,5 a pyrazine; G protein coupled receptors; Neuropeptides; Orexin receptors; Sleep

Indexed keywords

5,6,7,8 TETRAHYDROIMIDAZO[1,5 A]PYRAZINE DERIVATIVE; ALMOREXANT; IMIDAZOLE DERIVATIVE; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN RECEPTOR ANTAGONIST; PYRAZOLO TETRAHYDROPYRIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; TETRAHYDROISOQUINOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; MALE; NONHUMAN; RAT; RECEPTOR BLOCKING; STEREOCHEMISTRY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; PYRAZINES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875219067     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.01.088     Document Type: Article

References (34)

1. L. de Lecea, T.S. Kilduff, C. Peyron, X. Gao, P.E. Foye, P.E. Danielson, C. Fukuhara, E.L. Battenberg, V.T. Gautvik, F.S. Bartlett II, W.N. Frankel, A.N. van den Pol, F.E. Bloom, K.M. Gautvik, and J.G. Sutcliffe Proc. Natl. Acad. Sci. U.S.A. 95 1998 322
2. T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R.M. Chemelli, H. Tanaka, S.C. Williams, J.A. Richardson, G.P. Kozlowski, S. Wilson, J. Arch, R.E. Buckingham, A.C. Haynes, S.A. Carr, R.S. Annan, D.E. McNulty, W. Liu, J.A. Terrett, N.A. Elshourbagy, D.J. Bergsma, and M. Yanagisawa Cell 92 1998 573
3. L. Lin, J. Faraco, R. Li, H. Kadotani, W. Rogers, X. Lin, X. Qiu, P.J. de Jong, S. Nishino, and E. Mignot Cell 98 1999 365
4. R.M. Chemelli, J.T. Willie, C.M. Sinton, J.K. Elmquist, T. Scammell, C. Lee, J.A. Richardson, S.C. Williams, Y. Xiong, Y. Kisanuki, T.E. Fitch, M. Nakazato, R.E. Hammer, C.B. Saper, and M. Yanagisawa Cell 98 1999 437
5. For recent reviews on the medicinal chemistry of orexin antagonists: A.J. Roecker, and P.J. Coleman Curr. Top. Med. Chem. 8 2008 977
6. C. Boss, C. Brisbare-Roch, F. Jenck, H. Aissaoui, R. Koberstein, T. Sifferlen, and T. Weller Chimia 62 2008 974
7. C. Boss, C. Brisbare-Roch, and F. Jenck J. Med. Chem. 52 2009 891
8. J. Gatfield, C. Brisbare-Roch, F. Jenck, and C. Boss ChemMedChem 5 2010 1197
9. P.J. Coleman, and J.J. Renger Expert Opin. Ther. Pat. 20 2010 307
10. P.J. Coleman, C.D. Cox, and A.J. Roecker Curr. Top. Med. Chem. 11 2011 696
11. J.A. Christopher Pharm. Pat. Analyst 1 2012 329
12. 2R.
13. C. Brisbare-Roch, J. Dingemanse, R. Koberstein, P. Hoever, H. Aissaoui, S. Flores, C. Mueller, O. Nayler, J. van Gerven, S.L. de Haas, P. Hess, C. Qiu, S. Buchmann, M. Scherz, T. Weller, W. Fischli, M. Clozel, and F. Jenck Nat. Med. 13 2007 150
14. R. Koberstein, H. Aissaoui, D. Bur, M. Clozel, W. Fischli, F. Jenck, C. Mueller, O. Nayler, T. Sifferlen, A. Treiber, and T. Weller Chimia 57 2003 270
15. T. Sifferlen, C. Boss, E. Cottreel, R. Koberstein, M. Gude, H. Aissaoui, T. Weller, J. Gatfield, C. Brisbare-Roch, and F. Jenck Bioorg. Med. Chem. Lett. 20 2010 1539
16. Previous structure-activity relationship studies in the tetrahydroisoquinoline and pyrazolo-tetrahydropyridine series have indicated that two substituents are mandatory for the aryl or heterocycle moiety in order to reach potent affinities with both orexin receptors. Imidazoles were considered as a valuable heterocyclic replacement for the dimethoxyphenyl moiety due to the fact that they can be conveniently disubstituted, and the versatile chemistry of imidazoles allows the introduction of diverse substituents having different electronic properties.
17. 2-Substituted imidazoles 1 used for the investigations are either commercially available or specifically synthesized (Scheme 3). Substituents R corresponding to these 2-substituted imidazoles 1 are listed in Table 2.
18. S.J. Wittenberger, A. Tasker, B.K. Sorensen, and B.G. Donner Synth. Commun. 23 1993 3231
19. For recent reviews on halogen/magnesium exchange: M. Abarbri, J. Thibonnet, L. Berillon, F. Dehmel, M. Rottlaender, and P. Knochel J. Org. Chem. 65 2000 4618
20. P. Knochel, W. Dohle, N. Gommermann, F.F. Kneisel, F. Kopp, T. Korn, I. Sapountzis, and V.A. Vu Angew. Chem., Int. Ed. 42 2003 4302
21. Polyhalogenated imidazoles undergo halogen/magnesium or halogen/lithium exchange in a specific sequence (C2 > C5 > C4), under the appropriate reaction conditions: B. Iddon, and B.L. Lim J. Chem. Soc., Perkin Trans. 1 4 1983 735
22. M.P. Groziak, and L. Wei J. Org. Chem. 56 1991 4296
23. D.S. Carver, S.D. Lindell, and E.A. Saville-Stones Tetrahedron 53 1997 14481
24. R.H.-J. Butz, and S.D. Lindell J. Org. Chem. 67 2002 2699
25. C.J. Lovely, H. Du, and H.V.R. Dias Heterocycles 60 2003 1
26. For recent reviews on Pictet-Spengler reaction: K. Pulka Curr. Opin. Drug Discov. Dev. 13 2010 669
27. J. Stockigt, A.P. Antonchick, F.-R. Wu, and H. Waldmann Angew. Chem., Int. Ed. 50 2011 8538
28. Q.-Y. Chen, and S.-W. Wu J. Chem. Soc., Chem. Commun. 11 1989 705
29. M. Wolter, G. Nordmann, G.E. Job, and S.L. Buchwald Org. Lett. 4 2002 973
30. C.J. Lovely, H. Du, and H.V.R. Dias Org. Lett. 3 2001 1319
31. F. Cachoux, T. Isarno, M. Wartmann, and K.-H. Altmann Synlett 2006 1384
32. R.P. Frutos, I. Gallou, D. Reeves, Y. Xu, D. Krishnamurthy, and C.H. Senanayake Tetrahedron Lett. 46 2005 8369
33. R.P. Frutos, S. Rodriguez, N. Patel, J. Johnson, A. Saha, D. Krishnamurthy, and C.H. Senanayake Org. Process Res. Dev. 11 2007 1076
34. K.L. Kirk J. Org. Chem. 43 1978 4381